Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed solid tumor, including the following tumor types:
• •* Breast cancer
• •* Non-small cell lung cancer
• •* Prostate cancer
• •* Bladder cancer
• •* Gastroesophageal junction cancer
• •* Ovarian cancer
• •* Germ cell tumor
• •Advanced or metastatic disease
• •No effective curative therapy exists
• •Evaluable disease
• •* Measurable disease not required
• •* Bone-only disease allowed
• •No progressing brain metastases
• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-2
• •Life expectancy \> 3 months
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Hemoglobin ≥ 9.0 g/dL
• •Platelet count ≥ 100,000/mm\^3
• •Bilirubin normal
• •AST/ALT ≤ 2.5 times upper limit of normal
• •Creatinine normal
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No serious intercurrent medical or psychiatric illness
• •No serious active infection
• •No gastrointestinal tract disease that would impair a patient's ability to take oral medication
• •No history of significant cardiac disease, including any of the following:
• •* Congestive heart failure
• •* Symptomatic cardiac arrhythmias
• •* Unstable angina
• •No pre-existing peripheral neuropathy ≥ 2
• •PRIOR CONCURRENT THERAPY:
• •Any number of prior therapies allowed
• •Prior paclitaxel, tyrosine kinase inhibitor therapy, or endothelial growth factor inhibitors allowed
• •At least 14 days since prior and no concurrent CYP3A4 inducers or herbal or dietary supplements
• •At least 7 days since prior and no concurrent CYP3A4 inhibitors
• •At least 6 months since prior and no concurrent amiodarone
• •More than 1 month since prior chemotherapy, radiotherapy, hormonal therapy, or investigational anticancer agents
• •Concurrent continued use of gonadal suppression agents (i.e., goserelin acetate or leuprolide acetate) allowed
• •No antacids 1 hour before and after study drug administration
• •No concurrent retinoids
• •No concurrent hormonal anticancer agent
• •No other concurrent anticancer chemotherapy or investigational anticancer agents